Editas Medicine (EDIT) Preferred Dividend Payments (2015 - 2016)
Editas Medicine (EDIT) reported Preferred Dividend Payments of $47000.0 for Q1 2016, down 50.53% year-over-year from $95000.0 in Q2 2015, and down 52.53% on a QoQ basis from $99000.0 in Q4 2015.
Editas Medicine (EDIT) has 2 years of Preferred Dividend Payments data on file, last reported at $47000.0 in Q1 2016.
- Quarterly Preferred Dividend Payments fell 50.53% year-over-year to $47000.0 in Q1 2016, while the trailing twelve-month figure through Dec 2016 was $47000.0 (down 88.07% YoY) and the FY2016 annual result came in at $47000.0, down 88.07% from the prior year.
- Preferred Dividend Payments fell to $47000.0 in Q1 2016 per EDIT's latest filing, from $99000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $104000.0 in Q3 2015 and bottomed at $47000.0 in Q1 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 47,000.00 |
| Dec 31, 2015 | 99,000.00 |
| Sep 30, 2015 | 104,000.00 |
| Jun 30, 2015 | 96,000.00 |
| Mar 31, 2015 | 95,000.00 |